Churg-Strauss Syndrome (Allergic Vasculitis): Causes, Symptoms, Diagnosis, and Treatment
Churg-Strauss syndrome, also known as eosinophilic granulomatosis with polyangiitis (EGPA), is a rare form of systemic vasculitis that predominantly affects small and medium-sized blood vessels. The disease is characterized by a typical triad of bronchial asthma, peripheral eosinophilia, and multisystem vascular inflammation, and was first described in 1951 by Dr. Jacob Churg and Dr. Lotte Strauss. Its particularity lies in its association with allergic conditions, which differentiates it from other types of autoimmune vasculitis.
In this article, we will discuss the mechanisms of disease onset, clinical manifestations, current diagnostic criteria and available therapeutic options, as well as the long-term implications of living with EGPA and current research directions.
What is Churg-Strauss Syndrome or Small Vessel Vasculitis?
Photo source: Shutterstock.com
Churg-Strauss Syndrome, currently named Eosinophilic Granulomatosis with Polyangiitis (EGPA), is a rare form of systemic vasculitis that primarily affects small and medium-sized blood vessels. The disease is characterized by an aberrant immune response involving vascular inflammation, eosinophilic tissue infiltration, and frequently, the presence of asthma or other atopic conditions.
first described in 1951 by physicians Churg and Strauss, the condition typically progresses in three clinical phases. The allergic phase is marked by respiratory symptoms such as allergic rhinitis and asthma — often severe and refractory to treatment. In the eosinophilic phase, a marked increase in eosinophils is observed in the blood and various organs, such as the lungs or gastrointestinal tract. Subsequently, in the vasculitic phase, blood vessel inflammation becomes evident, systemically affecting multiple organs and causing neurological, cutaneous, cardiac, or renal manifestations.
EGPA is often associated with eosinophilic asthma, and this clinical overlap justifies rigorous monitoring of patients with persistent eosinophilia and chronic respiratory symptoms. Systemic manifestations may include polyneuropathy, cutaneous purpura, renal, or cardiac involvement, depending on the severity of vascular inflammation.
The exact cause of the disease is not fully elucidated, but autoimmune mechanisms, combined with genetic and environmental factors (such as exposure to allergens or certain medications), appear to play an important role. Treatment is based on the administration of systemic corticosteroids, in combination with immunosuppressive agents in severe or refractory cases.
Given the systemic inflammatory nature of the disease, general support of the immune system is essential. In this regard, essential fatty acids Omega 3, 6, and 9 can help reduce chronic inflammation and maintain immunological balance. Supplements such as Premium Omega 3-6-9 Vegan can be useful as an adjunct in a comprehensive therapeutic plan, supporting vascular, metabolic, and cellular health, under medical supervision.
[cta_produs style=”style_1″ product=”91518″ image=”https://aronia-charlottenburg.com/wp-content/uploads/2025/04/Ce-reprezinta-sindromul-Churg-Strauss-sau-boala-vaselor-de-sange-subtiri_-Aronia-HERO-product.png”]
Causes and Risk Factors Specific to Churg-Strauss Syndrome
The etiopathogenesis of Churg-Strauss syndrome (eosinophilic granulomatosis with polyangiitis) remains incompletely elucidated. Current data suggest a multifactorial contribution. This involves the interaction between genetic predisposition. This involves the interaction between environmental factors. This involves the interaction between immune dysfunction. Viewed from a medical perspective, this rare autoimmune disease is characterized by an exaggerated immune response. Within this response, the immune system erroneously attacks its own tissues. This attack generates eosinophilic inflammation. This attack generates multisystemic vascular lesions.
The genetic component plays a significant role. This role is especially in the context of genetic polymorphisms associated with the immune system. Variations in the major histocompatibility complex (particularly HLA-DRB1 and HLA-DQ genes) have been correlated with an increased susceptibility to disease development. Additionally, polymorphisms in genes regulating pro-inflammatory cytokine synthesis (such as IL-5 or IL-10) can amplify eosinophilic inflammation. These polymorphisms can contribute to persistent activation of T helper type 2 (Th2) lymphocytes. Th2 lymphocytes are involved in the allergic response.
Environmental factors can act as triggers in genetically predisposed individuals. These include inhaled allergens. These include respiratory viral infections. These include respiratory bacterial infections. These include certain medications. An example of medications are leukotriene inhibitors used in asthma treatment. An association has been observed between the use of these medications and disease onset. A direct causal relationship has not been established. Rather, there is latent immune activation in an already predisposed patient.
Eosinophilia – Role in Inflammation Pathogenesis
A central element of pathogenesis is marked eosinophilia. This involves eosinophil infiltration into tissues. This involves the secretion of cytotoxic mediators (such as eosinophilic cationic protein – ECP). This involves the secretion of cytotoxic mediators (such as major basic protein – MBP). These mediators contribute to tissue destruction. These mediators contribute to granuloma formation. These mediators contribute to perivascular inflammation. Eosinophils do not act in isolation. They act within the context of an activated immune network. In this network, T lymphocytes play their pro-inflammatory role. In this network, dendritic cells play their pro-inflammatory role. In this network, neutrophils play their pro-inflammatory role.
Autoimmunity is supported by the presence of ANCA (anti-neutrophil cytoplasmic antibodies) in 30-40% of patients. This is especially true in active vasculitic forms. This serological marker indicates systemic neutrophil activation. It is often associated with more severe manifestations. Examples of severe manifestations include glomerulonephritis. An example of a severe manifestation is peripheral neuropathy.
Although the disease can occur at any age, the incidence is higher among adults between 40 and 60 years old. A history of bronchial asthma is frequently found. A history of allergic rhinitis is frequently found. A history of nasal polyps is frequently found. These chronic respiratory comorbidities usually precede the development of systemic manifestations for years. This suggests a progressive evolution from localized allergic inflammation to systemic vascular inflammation.
Symptoms and Clinical Manifestations of Churg-Strauss Syndrome
The clinical presentation of Churg-Strauss syndrome is heterogeneous and typically evolves in three clinical phases, which do not always follow a strict sequence and may coexist or alternate during the course of the disease. The duration of each stage varies significantly from one patient to another, and the severity of symptoms is influenced by the degree of systemic involvement.
The prodromal (allergic) phase is characterized by atopic manifestations with insidious onset. Patients frequently present with severe bronchial asthma, adult-onset, persistent allergic rhinitis, chronic sinusitis, and often nasal polyposis. This stage can persist for years before progressing to more systemic forms of the disease and may respond partially to corticosteroid therapy.
Photo source: Shutterstock.com
The eosinophilic phase is dominated by marked eosinophilia, both in peripheral blood (over 1500 eosinophils/mm³) and in tissue infiltrates. Eosinophilic pneumonias (with cough, dyspnea, migratory pulmonary infiltrates), eosinophilic gastroenteritis (manifesting as abdominal pain, nausea, diarrhea), and general symptoms such as fever, myalgia, and fatigue are frequently observed. Cutaneous involvement is relatively common, represented by purpuric lesions, subcutaneous nodules, or recurrent urticaria, with a predilection for the lower extremities.
Vasculitis – Neurological Manifestations and Progression
The vasculitic phase marks the progression to the fully developed form of the disease and is characterized by necrotizing inflammation of small and medium-sized blood vessels, with severe systemic involvement. Peripheral neuropathy, particularly mononeuritis multiplex, is one of the most common neurological manifestations and occurs in up to 70% of patients, causing pain, paresthesia, and asymmetrical muscle weakness. Central nervous system involvement is rarer, but strokes, seizures, or confusional states may occur.
Cardiac involvement, which is the main cause of mortality in Churg-Strauss syndrome, can include eosinophilic myocarditis, endomyocardial fibrosis, pericarditis, or coronary vasculitis, with an increased risk of heart failure and arrhythmias. Gastrointestinal involvement is reported in one-third of patients, having inflammatory or ischemic mechanisms (mesenteric ischemia), and renal manifestations, although rarer, can progress to necrotizing glomerulonephritis.
Musculoskeletal manifestations, such as arthralgia, myalgia, and arthritis, are common in all phases of the disease, contributing to the systemic inflammatory syndrome. The overall severity of the disease is dictated by the number and gravity of the affected organs, and cardiac, renal, neurological, or gastrointestinal involvement is associated with a poor prognosis.
Diagnosing Churg-Strauss Syndrome
The diagnosis of Churg-Strauss syndrome (eosinophilic granulomatosis with polyangiitis) is complex, as symptoms vary considerably from patient to patient and can mimic other inflammatory, allergic, or autoimmune diseases. Being a rare condition, the diagnosis is based on a combination of clinical criteria, laboratory tests, imaging investigations, and, in some cases, histopathological confirmation.
The diagnostic process begins with a detailed medical history, during which the physician aims to identify key symptoms such as adult-onset bronchial asthma, chronic allergic rhinitis, recurrent sinusitis, and progressive systemic manifestations. The physical examination may reveal signs such as pulmonary wheezing, cutaneous purpura, subcutaneous nodules, or peripheral neurological deficits (e.g., mononeuropathies).
Essential laboratory tests in the evaluation include:
- Complete blood count, which typically shows marked eosinophilia (>1500/mm³), one of the fundamental characteristics of the disease.
- Inflammatory markers (ESR, CRP) are frequently elevated, indicating active inflammatory processes.
- ANCA serological tests, with p-ANCA (anti-myeloperoxidase antibodies) positive in about 30-40% of cases. However, the presence or absence of ANCA does not exclude the disease.
- Renal and hepatic function tests, useful for assessing target organ damage.
On the other hand, imaging studies provide valuable information about pulmonary and sinus involvement:
- Chest X-ray orpulmonary CT scan may reveal migratory infiltrates, nodules, alveolar opacities, or signs of pulmonary fibrosis.
- Sinus CT scan helps identify chronic sinusitis, often present in the prodromal phase.
- In selected cases,angiography may be used to detect vasculitic changes in small and medium-sized vessels.
Concurrently, pulmonary function tests, particularly spirometry, may show a reversible obstructive pattern, characteristic of severe bronchial asthma.
However, biopsy remains the gold standard for confirming the diagnosis. Tissue sampling (skin, lung, kidney, or nerve) frequently reveals the histological triad: necrotizing vasculitis, massive eosinophilic infiltrate, and extravascular granulomas.
In certain situations, the physician may recommendbronchoalveolar lavage (via bronchoscopy), especially to rule out other pulmonary pathologies. An increased number of eosinophils in the lavage fluid can support the diagnosis in the appropriate clinical context.
Last but not least, cardiac evaluation is essential, given the frequency and severity of cardiac involvement in EGPA. Investigations include electrocardiogram (ECG), transthoracic echocardiography, and, if necessary, cardiac MRI, to detect myocarditis or other functional abnormalities.
Treatment of Churg-Strauss Syndrome
The treatment of Churg-Strauss syndrome (eosinophilic granulomatosis with polyangiitis) aims to control systemic inflammation, prevent disease progression and organ damage, and induce lasting remission. The therapeutic strategy is personalized according to the severity of the disease, the organs involved, and the patient’s response to medication, often requiring a multidisciplinary approach.
Remission induction therapy begins with the administration of systemic corticosteroids, usually in high doses (e.g., prednisone 1 mg/kg/day), to rapidly control inflammation and reduce eosinophil counts. In severe cases, characterized by vital organ involvement (cardiac, renal, neurological), the addition of immunosuppressive agents such as cyclophosphamide is indicated to potentiate the therapeutic response and prevent irreversible tissue damage.
After remission is achieved, the maintenance phase follows, during which the corticosteroid dose is gradually reduced to minimize long-term adverse effects (osteoporosis, steroid-induced diabetes, cataracts, increased risk of infections). In this stage, an immunomodulatory drug with a better safety profile, such as azathioprine, methotrexate, or mycophenolate mofetil, is often introduced.
Biologics – Options for Refractory Disease
For patients with refractory disease or intolerance to conventional treatments, biologic therapies targeting specific disease mechanisms are available. Mepolizumab, an anti-IL-5 monoclonal antibody approved for EGPA, has proven effective in reducing relapses and controlling respiratory symptoms by reducing eosinophil counts. Rituximab may also be used in ANCA-positive forms, especially when an alternative to cyclophosphamide is needed.
Management of comorbidities, particularly bronchial asthma, remains essential throughout the disease course. Standard inhaler treatment with inhaled corticosteroids and long-acting bronchodilators is maintained, supplemented as needed with anti-IL-5 biologic therapies.
Throughout treatment, close monitoring of biological parameters, affected organ function, and possible adverse reactions to therapy is mandatory. Prophylactic measures against opportunistic infections, osteoporosis, and hypertension are also recommended, especially in patients receiving chronic corticosteroid therapy.
Complications of Churg-Strauss Syndrome
Complications of Churg-Strauss syndrome are varied, can involve multiple systems, and may rapidly progress to severe or irreversible damage if the disease is not diagnosed and treated appropriately. These result from the systemic inflammatory process, dominated by eosinophilic infiltration and vascular lesions that reduce tissue perfusion and compromise the function of affected organs.
At the pulmonary level, persistent infiltrates may occur, which, over time, can lead to pulmonary fibrosis and the development of chronic respiratory failure. A rare but serious complication is diffuse alveolar hemorrhage, a medical emergency associated with severe hypoxia and life-threatening risk.
Cardiac involvement is one of the main causes of mortality in Churg-Strauss. Myocardial inflammation can lead to eosinophilic cardiomyopathy, arrhythmias, congestive heart failure, and in some cases, prolonged inflammation of the pericardium can cause constrictive pericarditis.
Photo source: Shutterstock.com
Peripheral and Central Nervous System Involvement in Vasculitis
The peripheral nervous system is frequently affected by the onset of peripheral neuropathy, particularly mononeuritis multiplex, which can persist even after remission of active disease. In rare cases, cerebral vasculitis can cause strokes, manifested by focal neurological deficits, seizures, or altered consciousness.
Renal involvement, although less common compared to other ANCA-positive vasculitides, can progress to necrotizing glomerulonephritis or rapidly progressive glomerulonephritis, with a risk of acute kidney failure. Gastrointestinal tract involvement can include eosinophilic gastroenteritis, mesenteric ischemia, or gastrointestinal bleeding, with a life-threatening potential.
In addition to complications caused by the disease itself, the intensive immunosuppressive therapy required for inflammation control carries its own risks. Prolonged administration of corticosteroids and cytotoxic agents is associated with severe osteoporosis, steroid-induced diabetes, hypertension, cataracts, but especially with an increased risk of opportunistic infections.
Considering these risks, it is essential that patients with Churg-Strauss syndrome are regularly monitored through clinical, biological, and imaging assessments, and that treatment is adjusted according to disease activity and individual risk profile. Thus, effective management and early intervention in the face of complications are crucial for reducing morbidity and improving long-term prognosis.
Implications of Living with Churg-Strauss Syndrome
The daily life of a person diagnosed with Churg-Strauss syndrome (eosinophilic granulomatosis with polyangiitis) involves continuous adaptation to a chronic, autoimmune, and systemic condition, which requires not only pharmacological treatments but also sustained personal care measures. Beyond clinical control of inflammation and prevention of complications, patients must reorganize their activities and lifestyle according to the disease’s progression and response to treatment.
Firstly, managing respiratory symptoms (such as bronchial asthma) and systemic manifestations, such as chronic fatigue, muscle pain, or peripheral neuropathy, requires a functional approach, including planning daily activities and avoiding known trigger factors (such as allergens or respiratory infections). Adherence to prescribed treatment and continuous monitoring of biological and clinical parameters are essential conditions for long-term disease control.
For many patients, the disease necessitates changes in their professional environment. Collaboration with employers to adjust work schedules or physical tasks can help maintain professional activity without compromising health. Concurrently, psychological support and emotional backing from family, friends, or patient groups play an important role in adapting to the psychosocial impact of chronic illness.
Regular multidisciplinary monitoring — including rheumatologists, pulmonologists, neurologists, and other specialists — is indispensable for assessing disease activity and early adjustment of therapy based on potential relapses or adverse effects. Furthermore, patients must be aware of the risks associated with immunosuppressive therapy, and infection prevention, calcium/vitamin D supplementation, and periodic screening are essential to avoid treatment complications.
Overall, living with Churg-Strauss syndrome involves a personalized chronic management strategy, focused not only on disease control but also on maintaining the best possible quality of life, despite the limitations imposed by this rare vasculitis.
Scientific Advances in the Pathogenesis and Management of Churg-Strauss Syndrome
Current research in eosinophilic granulomatosis with polyangiitis (EGPA), formerly known as Churg-Strauss syndrome, has advanced considerably. Research offers new insights into the pathogenic mechanisms involved. Research contributes to the development of more targeted therapeutic strategies. Research contributes to the development of more effective therapeutic strategies. In other words, recent progress focuses primarily on T helper type 2 (Th2) cell-mediated immune dysfunction. Recent progress focuses on the central role played by eosinophils in the systemic inflammation characteristic of the disease. Recent progress focuses on the central role played by eosinophils in the tissue inflammation characteristic of the disease.
Among the major discoveries is the involvement of Th2 cytokines. Examples of Th2 cytokines are interleukin-5 (IL-5). Other examples are IL-4 and IL-13. These cytokines facilitate eosinophil activation. These cytokines facilitate eosinophil proliferation. These cytokines facilitate eosinophil migration into tissues. Overexpression of these pro-inflammatory mediators contributes to eosinophilic infiltration. It contributes to the formation of extravascular granulomas. These are essential pathological mechanisms in EGPA. More specifically, this immunological context has supported the introduction of targeted biological therapies. An example of targeted biological therapy is anti-IL-5 monoclonal antibodies (e.g., mepolizumab). These have proven effective in reducing disease activity. They have proven effective in reducing the need for corticosteroids. They have proven effective in preventing relapses.
Furthermore, current studies aim to identify specific biomarkers. These would allow for earlier diagnosis. They would allow for more accurate disease monitoring. Research in transcriptomics has revealed distinct molecular profiles in serum. It has revealed distinct molecular profiles in peripheral blood mononuclear cells of EGPA patients. These include specific circulating microRNA patterns. These biomarkers could, in the future, allow for more precise differentiation of EGPA from other forms of ANCA-associated systemic vasculitis.
Advanced Imaging Techniques – Vasculitis Assessment
Moving beyond immunological advances, the use of advanced imaging techniques is also being explored. An example is positron emission tomography (PET-CT) with inflammatory radiotracers. The goal is to quantify the degree of vasculitic activity. The goal is to identify affected tissues. This is done without resorting to invasive procedures. These imaging methods can become valuable tools for assessing treatment response. They can become valuable tools for guiding therapeutic decisions.
In the direction of precision medicine, predictive models are being developed. These are based on the integration of clinical data. They are based on the integration of genetic data. They are based on the integration of molecular data. The goal is to personalize treatment. The goal is to anticipate disease progression. Thus, classifying patients according to their immunological profile could lead to more effective therapeutic stratification. Classification according to their genetic profile could lead to more effective therapeutic stratification. This would reduce the risks of immunomodulatory treatment. It would increase the chances of sustained remission.
Despite Churg-Strauss syndrome being a rare chronic disease, therapeutic advances in recent years have significantly improved the prospects for controlling the condition. The disease has complex manifestations. The disease has, at times, unpredictable manifestations. The introduction of personalized treatments allows for effective symptom management. It allows for reduction of the risk of long-term complications. The introduction of multidisciplinary monitoring allows for effective symptom management. It allows for reduction of the risk of long-term complications. Thus, with a correct and individualized approach, many patients can maintain a good quality of life. Furthermore, ongoing scientific research supports the hope for increasingly effective therapeutic options. These options are designed to best meet the individual needs of people diagnosed with this condition.
References:
1. Groh M, Pagnoux C, Baldini C, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. Eur J Intern Med. 2015;26(7):545-553. https://doi.org/10.1016/j.ejim.2015.04.022;
2. Cottin V, Bel E, Bottero P, et al. Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss): A study of 157 patients by the Groupe d’Etudes et de Recherche sur les Maladies Orphelines Pulmonaires and the European Respiratory Society Taskforce on eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Autoimmun Rev. 2017;16(1):1-9. https://doi.org/10.1016/j.autrev.2016.09.018;
3. Furuta S, Iwamoto T, Nakajima H. Update on eosinophilic granulomatosis with polyangiitis. Allergol Int. 2019;68(4):430-436. https://doi.org/10.1016/j.alit.2019.06.004;
4. Trivioli G, Terrier B, Vaglio A. Eosinophilic granulomatosis with polyangiitis: understanding the disease and its management. Rheumatology (Oxford). 2020;59(Suppl 3):iii84-iii94. https://doi.org/10.1093/rheumatology/kez570;
5. Moosig F, Bremer JP, Hellmich B, et al. A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): monocentric experiences in 150 patients. Ann Rheum Dis. 2013;72(6):1011-1017. https://doi.org/10.1136/annrheumdis-2012-201531.
Photo source: Shutterstock.com